0001209191-24-002929.txt : 20240206 0001209191-24-002929.hdr.sgml : 20240206 20240206175739 ACCESSION NUMBER: 0001209191-24-002929 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240202 FILED AS OF DATE: 20240206 DATE AS OF CHANGE: 20240206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Agger Mette Kirstine CENTRAL INDEX KEY: 0001722234 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41855 FILM NUMBER: 24601482 MAIL ADDRESS: STREET 1: C/O SCPHARMACEUTICALS, INC. STREET 2: 2400 DISTRICT AVENUE SUITE 310 CITY: BURLINGTON STATE: MA ZIP: 01830 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lexeo Therapeutics, Inc. CENTRAL INDEX KEY: 0001907108 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 854012572 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 345 PARK AVENUE SOUTH STREET 2: FLOOR 6 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: (212) 547-9879 MAIL ADDRESS: STREET 1: 345 PARK AVENUE SOUTH STREET 2: FLOOR 6 CITY: NEW YORK STATE: NY ZIP: 10010 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-02-02 0 0001907108 Lexeo Therapeutics, Inc. LXEO 0001722234 Agger Mette Kirstine C/O LEXEO THERAPEUTICS, INC. 345 PARK AVENUE SOUTH, FLOOR 6 NEW YORK NY 10010 1 0 0 0 0 Stock Option (right to buy) 17.00 2024-02-02 4 A 0 36000 0.00 A 2034-02-01 Common Stock 36000 36000 D 25% of the shares underlying the option shall vest and become exercisable on November 2, 2024, and 1/48th of the shares underlying the option shall vest in equal monthly installments thereafter, subject to the Reporting Person's continuous service. /s/ Jenny Robertson, attorney-in-fact 2024-02-06